Search

everythinglearnresearchcommunity

for

Search:↓

Selumetinib causes skin and hair side effects in kids with NF1, affecting treatment and quality of life.

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

Selumetinib significantly reduced tumor size and improved vision in a child with neurofibromatosis type 1.

Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.

The combination treatment showed a higher response rate but no significant survival benefits.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.

The combination of encorafenib and binimetinib caused few skin issues.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Trametinib can cause skin issues, but they can often be managed without stopping the drug.

Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.

Sorafenib can cause a unique skin reaction.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

Gefitinib can cause hair and eyebrow darkening.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Tadalafil and Finasteride may help treat aggressive melanoma.

Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.

Ritlecitinib can help about 14,000 people with severe hair loss.

Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.